Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma (LIFT)

Clinical Trial ID NCT01275209

PubWeight™ 5.58‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01275209

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2015 1.54
2 Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med 2015 1.04
3 Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol 2012 0.82
4 Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy 2015 0.81
5 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
6 Target Therapy in Hematological Malignances: New Monoclonal Antibodies. Int Sch Res Notices 2014 0.76
Next 100